Dr Andrei Iagaru joins Clarity’s Scientific Advisory Board
Sydney, Australia 5 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Andrei Iagaru has joined Clarity’s Scientific Advisory Board (SAB). Dr Iagaru is a Professor of Radiology – Nuclear Medicine and the Chief of the Division of…